|
The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters |
Elshout M, van der Reis MI, Webers CA, Schouten JS |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Elshout M, van der Reis MI, Webers CA, Schouten JS. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefe's Archive for Clinical and Experimental Ophthalmology 2014: epub Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Angiogenesis Inhibitors /economics /therapeutic use; Antibodies, Monoclonal, Humanized /economics /therapeutic use; Bevacizumab; Cost-Benefit Analysis; Drug Costs; Female; Health Care Costs; Humans; Intravitreal Injections; Macular Degeneration /drug therapy /economics; Male; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Ranibizumab; Receptors, Vascular Endothelial Growth Factor /economics /therapeutic use; Recombinant Fusion Proteins /economics /therapeutic use; Vascular Endothelial Growth Factor A /antagonists & Visual Acuity /physiology; inhibitors AccessionNumber 22014019550 Date bibliographic record published 19/11/2014 |
|
|
|